Aquaflor® is an aquaculture premix containing florfenicol and is only available through Merck Animal Health. Aquaflor® medicated feed can be purchased through aquaculture feed mills. The primary goal of field studies conducted under INAD #10-697 is to evaluate the efficacy of florfenicol-medicated feed for controlling mortality in lobsters (Nephropidae and Palinuridae) with a variety of diseases that are caused by pathogens susceptible to florfenicol. The primary pathogen of interest is Photobacterium indicum. Two treatment options are allowed; administer Aquaflor® in feed at either 10 or 15 mg active florfenicol per kg lobster per day for 10 consecutive days. The Investigational withdrawal period is dependent upon dosage administered; 21 days for 10 mg/kg and 28 days for 15 mg/kg. To participate in the INAD Program for Aquaflor® visit the data collecting site.
Please read the Study Protocol prior to any treatments. It contains the protocol, MSDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson .
INAD objective/purpose: Collect supportive and pivotal data needed to establish the effectiveness of florfenicol to control mortality caused by certain bacterial diseases in lobsters.
Merck Animal Health
35500 W. 91st Street
De Soto, KS 66018
Kasha M. Cox
Target pathogen(s): Bacterial pathogens susceptible to florfenicol, although the primary bacterial pathogen of interest is Photobacterium indicum.
Method of administration: Medicated feed treatment
Investigational Withdrawal period:
Required test parameters:
Limitations or restrictions on use of drug:
Required INAD fee: $700/facility/year
AADAP Contact Information:
Ms. Bonnie Johnson, FWS-AADAP